Vertex Pharma (VRTX) Posts Smaller Q3 Loss, Revs Top Views
Get Alerts VRTX Hot Sheet
Revenue Growth %: +8.9%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of ($0.37), $0.25 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $179 million versus the consensus estimate of $146.2 million.
Vertex's third quarter 2014 net product revenues from KALYDECO were $126.8 million compared to $101.1 million for the third quarter of 2013. The increased revenues, compared to the third quarter of 2013, resulted primarily from the use of KALYDECO in the U.S. in people with the additional mutations approved by the FDA in February 2014 and from an increase of approximately $7 million that resulted from changes in Vertex's distribution network.
"With the recent progress across our research and development programs in cystic fibrosis and the expansion of the number of people being treated with KALYDECO, we have established a clear path for the future of our company," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "We remain focused on investing in the discovery and development of new medicines for CF and other serious and rare diseases while increasing revenues to move us to profitability and drive earnings growth."
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
- Spotify (SPOT) PT Raised to $325 at CFRA
- Netflix (NFLX) bonds retain Outperform rating at Gimme Credit amid strong content ROI
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!